RDHLNasdaqPharmaceutical Preparations
RedHill Biopharma Ltd.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 27, 2026
$0.50+0.02 (+4.39%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
RedHill Biopharma Ltd. revenue by segment
By business segment
| Operating income | FY2024 | FY2023 | FY2022 | FY2020 | FY2019 | FY2018 | FY2017 | YoY |
|---|---|---|---|---|---|---|---|---|
| Commercial Operations | – | – | – | -$37.60M | -$18.00M | -$8.60M | -$11.32M | – |
| Research and Development | – | – | – | -$26.09M | -$25.21M | -$30.73M | -$40.65M | – |
By product or service
| Revenue | FY2024 | FY2023 | FY2022 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Talicia | $8.40M | $9.10M | $7.70M | – | – | – | – | 104.4% | -7.7% |
| Movantik | – | – | $52.10M | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of RedHill Biopharma's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.